PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1515611
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1515611
Asia Pacific HIV Injection Market, By Drug Type, By Distribution Channel, By Country - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
REPORT HIGHLIGHT
Asia Pacific HIV Injection Market size was valued at USD 390.93 million in 2023, expanding at a CAGR of 17.03% from 2024 to 2032.
HIV injections are injectable treatments used for managing HIV, a virus that attacks the body's immune system and can progress to AIDS if left untreated. These injections are part of antiretroviral therapy (ART), the standard treatment for HIV. One of the most popular long-acting injectable treatments for HIV is the Cabotegravir and Rilpivirine combination. In 2022, the World Health Organization (WHO) included CAB PrEP in its list of recommended options for HIV prevention, releasing guidelines for its use. By June 2023, CAB PrEP has only received regulatory approval in a few countries, with Australia being the sole country in the Asia-Pacific Region. While HIV infection rates are currently low in many Pacific regions, the potential for rapid spread exists once the virus enters small island populations. Countries such as Bangladesh, East Timor, Japan, Laos, Pakistan, and the Philippines continue to report minimal HIV prevalence, even among high-risk groups. These nations have a unique opportunity to prevent major outbreaks by taking immediate action. The financial support for HIV prevention and treatment, in addition to the existing AUD25 million partnership between UNAIDS and the Australian Government in the Asia Pacific region (2022-2027), signifies an expansion of their ongoing collaboration.
Asia Pacific HIV Injection Market- Market Dynamics
The Asia Pacific HIV Injection Market is anticipated to experience growth due to the increasing prevalence of HIV/AIDS and the growing demand for effective treatment options.
The increasing number of HIV/AIDS cases in the Asia Pacific region is creating a need for effective treatment options, including HIV injections. According to a Chinese medical journal, China has managed to keep the epidemic to less than 0.1% of HIV prevalence by the end of 2017. By October 2020, there were 1.045 million reported cases of people living with HIV/AIDS in China. As awareness about HIV/AIDS grows, there is a rising demand for efficient treatment options. HIV injections, such as long-acting antiretroviral therapies (ART), offer an alternative to daily oral medications, providing convenience and improved treatment adherence. Additionally, advancements in drug delivery systems and the development of long-acting injectables (LAIs) present significant growth opportunities for the market. However, the high cost of HIV injections and treatment may hinder market growth.
Asia Pacific HIV Injection Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 17.03% over the forecast period (2024-2032)
Based on Drug Type segmentation, polyethylene was predicted to show maximum market share in the year 2023
Based on Distribution Channel segmentation, automotive was the leading type in 2023
Based on countries, China was the leading revenue generator in 2023
Asia Pacific HIV Injection Market- Segmentation Analysis:
The Asia Pacific HIV Injection Market is segmented based on Drug Type, Distribution Channel, and Country.
The Asia Pacific HIV Injection market categorizes drugs into three groups: Antiretroviral therapy (ART), Pre-exposure Prophylaxis (PrEP), and Long-acting Injectables. ART injections aim to manage HIV and halt the development of AIDS. PrEP injections are utilized to prevent HIV transmission in at-risk communities. , Long-acting injectables offer continuous medication release, decreasing dosing frequency and enhancing patient adherence. They serve both as treatment and prevention for HIV.
The market is segmented into three categories according to Distribution channels: Hospital Pharmacy, Drugs Stores & Retail Pharmacies, and Others. The dominant category is others, which encompasses online pharmacies, community health centers, and NGOs, and is increasingly dominating the distribution channel for HIV injections.
Asia Pacific HIV Injection Market- Competitive Landscape:
Recent Developments:
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
Table of Contents
1. Asia Pacific HIV Injection Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.1.1. Asia Pacific HIV Injection Market Snippet by Drug Type
- 2.1.2. Asia Pacific HIV Injection Market Snippet by Distribution Channel
- 2.1.3. Asia Pacific HIV Injection Market Snippet by Country
- 2.2. Competitive Insights
3. Asia Pacific HIV Injection Key Market Trends
4. Asia Pacific HIV Injection Industry Study
5. Asia Pacific HIV Injection Market: COVID-19 Impact Analysis
6. Asia Pacific HIV Injection Market Landscape
7. Asia Pacific HIV Injection Market - By Drug Type
8. Asia Pacific HIV Injection Market - By Distribution Channel
9. Asia Pacific HIV Injection Market- By Geography
10. Key Vendor Analysis- Asia Pacific HIV Injection Industry
11. 360 Degree Analyst View
12. Appendix
List of Tables
- TABLE List of data sources
- TABLE Market drivers; Impact Analysis
- TABLE Market restraints; Impact Analysis
- TABLE Asia Pacific HIV Injection Market: Drug Type Snapshot (2023)
- TABLE Segment Dashboard; Definition and Scope, by Drug Type
- TABLE Asia Pacific HIV Injection Market, by Drug Type 2019-2032 (USD Million)
- TABLE Asia Pacific HIV Injection Market: Distribution Channel Snapshot (2023)
- TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
- TABLE Asia Pacific HIV Injection Market, by Distribution Channel 2019-2032 (USD Million)
- TABLE Asia Pacific Asia Pacific HIV Injection Market, by Country, 2019-2032 (USD Million)
List of Figures
